Circulating Metabolites as Biomarkers of Disease in Patients with Mesial Temporal Lobe Epilepsy
Sign Up to like & getrecommendations! Published in 2022 at "Metabolites"
DOI: 10.3390/metabo12050446
Abstract: A major challenge in the clinical management of patients with mesial temporal lobe epilepsy (MTLE) is identifying those who do not respond to antiseizure medication (ASM), allowing for the timely pursuit of alternative treatments such… read more here.
Keywords: lobe epilepsy; temporal lobe; patients mesial; biomarkers disease ... See more keywords